IP management@universities 2014 Best practices: Univ-Ind collaborations

Jo Bury, managing director VIB Istanbul, October 30 th -31 st , 2014

Policy factors impacting innovation: The case of Flanders

Jo Bury, managing director VIB

Flanders anno 1994 • • • well established support for R&D good (life) science stars of worldclass

Flanders anno 1994 • • • • well established support for R&D good (life) science stars of worldclass Innogenetics – Plant Genetic Systems How can we do better?

SWOT analysis Flanders 1994 • • • • S: - strong science base (champions) W: - no structural funding - brain drain - no tech transfer O: - develop an attraction pole of excellence - build a knowledge economy T: - loose leading position

Benchmarks • • • • • • Max Planck Society MRC UK Karolinska Institutet Cold Spring Harbor Labs Salk Institute HHMI

Preliminary conclusions • • • • • • Focus on excellence PI vs Dir as DMU Combine strenghts Build critical mass Build a tech transfer pipeline Develop a biotech cluster

Business plan • • build a new institute from scratch o attract the champions ↕ reunite the champions in 1 SRC o multisite o stringent selection

Business plan (2) • • • • thematic focus: o GE: molecular mechanism of life high level of ambition: o top 10% WW continuous improvement: o selection / continuation based on excellence institution: o not another granting body

Business plan (3) • • • long term financial commitment: o significant (30-50%) o 22 M€/year o 5 years o renewable (if excellent) stringent selection of university departments: o 9/100 independent structure (SRC): o board of directors o own facilities (TTO)

Reduction to practice • • • • Minister-President: o visionary (long term view) o right combination of powers o April 1994 government of Flanders: o April 1995 foundation by notarial deed: o July 1995 operations: o January 1996

Reduction to practice (2) Partnership with universities • • • • • university campus empower univ staff with VIB staff framework agreement VIB-univ mutual added value share return on investment – Publications: 2 affiliations – IPR: joint IP (VIB in charge)

VIB today

VIB: Mission To create groundbreaking knowledge on the molecular mechanisms ruling life for the benefit of scientific progress and the benefit of society

Excellence in science + Excellence in tech transfer

VIB state of affairs • • • • • multisite institute (JV with univ) 1350 scientists – technicians (50/50) 76 research groups 8 departments management agreement (2012-2016) • 43.8 M€/year • • 5 years key performance indicators

Basic Research@VIB Molecular mechanisms • • molecular medecine – normal growth and development – health vs disease  neurobiology  cancer  inflammation  cardiovascular molecular farming – normal growth and development – normal vs stress

Basic Research@VIB • • • centre of excellence important biological questions stimulating environment – VIB grant – research infrastructure – disruptive technologies – dialective environment – institutional integration

Science policy Making the Difference • • • frontline (not me too) world class (international competition) relevance + quality performance = good record of high impact publications and patent applications

Results 2013

Results 2013 • • • 620 peer reviewed publications 168 breaktrough articles (68 T1%) 70 PhD’s

Publications in top journals (T5%) 180 160 140 120 100 80 60 40 20 0 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13

Excellence in tech transfer

Path towards value creation IPR Agreements Start-ups

An integrated and pro-active team IP Management License & BD deals Start-up Projects Business Development Assessment TT Projects Licensing case  New Ventures Start-up case

A proactive IP strategy 45 40 15 10 5 0 35 30 25 20 • VIB patent estate: 218 patent families non-VIB VIB

116 partnering agreements signed 140 120 100 80 60 40 20 0 95 96 97 98 99 00 '01 '02 '03 '04 '05 '06 '07 '08 '09 10 11 12 VIB 0 8 8 15 15 34 29 47 65 61 69 59 82 80 94 111 124 116

VIB integrated approach towards start-ups

VIB POC Fund Facilitate

start-up and early stage

Evaluate

technology & business opportunity Build IPR platform Perform

FTO

analysis Conceptualize and write

business plan

Search for

management

Road show to investors

Seed Capital Fund

VIB start-ups: from knowledge to products

608 employees

VIB start-ups: equity investment and exit 8 M€ + 29 M€ => IPO => Tradesale 5 M€ + 25 M€ + 11 M€ => Tradesale 5 M€ + 25M€ + 40 M€ => IPO 14.5 M€ + 7.9 M€ + 5.1 M€ 20 M€ + 15.5 M€ + 10.7M€ 2 M€ + 5.5M€ 2 M€ 5 M€

VIB start-ups: a magnet for foreign investments • Total investment in VIB start-ups (€) – VC/private – IPO/PIPE/SPO : : 255.200.000

272.500.000

527.700.000

~ 50% international

Products: therapeutic pipeline • 13 therapeutics under development, including 1 small compound

VIB as facilitator for the biotech sector Building networks Attracting/consolidating companies to/in Flanders Infrastructure

Bio-incubator Leuven

UGent Technology Park: Large Cluster in Biotech the largest R&D hub in AgBio in Europe DevGen arGEN-X VIB/UGent

Bioaccelerator I Bioaccelerator II

Ablynx Bayer Crop Science (former PGS) Innogenetics

IIC Ugent

Oxyrane, Genohm, Biogazelle, Feops, Com & Sciense, Quinvita, Bio Actor CropDesign Anabiotec

1900 employees

Fytolab

VIB Bioincubator

Actogenix, ADX Neuroscience, Biomaric, BIP, Complix, Pronota, Seps Pharma, Yakult, Q-Biologicals 34

Ghent Agrobiotech cluster

Ghent Biomed campus

From science to value

Policy factors impacting innovation: The case of Flanders

Jo Bury, managing director VIB

Science policy (2) Making the right Choices • • • • • • • • selecting on excellence bottom up approach strategic plan (15.10) exposure to SABs monitoring (w y m i w y g) evaluation reward excellence (rotation) VIB grant allocation ~ performance